Volume 30, Number 12—December 2024
Research
Clinical Manifestations, Antifungal Drug Susceptibility, and Treatment Outcomes for Emerging Zoonotic Cutaneous Sporotrichosis, Thailand
Pattriya Jirawattanadon, Sumanas Bunyaratavej, Charussri Leeyaphan, Piriyaporn Chongtrakool, Panitta Sitthinamsuwan, Waratchaya Panjapakkul, Suthasanee Prasertsook, Phuwakorn Saengthong-aram, Nicha Wareesawetsuwan, Julaluck Posri, and Penvadee Pattanaprichakul
Table 1
Patient demographics in study of clinical manifestations, antifungal drug susceptibility, and treatment outcomes for emerging zoonotic cutaneous sporotrichosis, Thailand*
| Demographic data | Sporotrichosis cases, n = 49 |
|---|---|
| Patient sex | |
| F | 32 (65.3) |
| M |
17 (34.7) |
| Mean age, y (±SD) | 58.7 (±16.9) |
| Median symptom duration, d (IQR) |
30 (21–60) |
| Immune status | |
| Immunocompetent host | 40 (81.6) |
| Immunocompromised host | 9 (18.4) |
| Diabetes mellitus | 8/9 (88.9) |
| Sigmoid carcinoma and recent chemotherapy |
1/9 (11.1) |
| Occupation | |
| Retired/unemployed | 15 (30.6) |
| Officer | 10 (20.4) |
| Merchant/business owner | 8 (16.3) |
| Veterinarian/veterinary assistants | 4 (8.2) |
| Student | 4 (8.2) |
| Housekeeper/cleaner | 4 (8.2) |
| Other† |
4 (8.2) |
| Exposure history | |
| Zoonosis | 35 (71.4) |
| Cats | 32/35 (91.4) |
| Insect bite | 3/35 (8.6) |
| Wound contact with soil | 1 (2.0) |
| Unknown | 13 (26.5) |
| Family history of cutaneous sporotrichosis |
5 (10.2) |
| Clinical symptoms | |
| Painless | 24 (49.0) |
| Painful | 19 (38.8) |
| Itching |
6 (12.2) |
| Lesions | |
| Median no. lesions (IQR) | 2.0 (1.0–3.0) |
| Single | 20 (40.8) |
| Multiple | 29 (59.2) |
| Unilateral | 25/29 (86.2) |
| Bilateral |
4/29 (13.8) |
| Morphology | |
| Nonpurulent, nonulcerative papule, plaque, or nodule | 34 (69.4) |
| Purulent, ulcerative pustule, ulcer, abscess |
15 (30.6) |
| Arrangement | |
| Satellite nodules around the ulcer rim | 27 (55.1) |
| Lymphocutaneous pattern |
22 (44.9) |
| Lesion site | |
| Head and neck | 3 (6.1) |
| Trunk | 1 (2.0) |
| Upper extremities | 36 (73.5) |
| Lower extremities | 11 (22.4) |
| Lymphadenopathy, n = 44 |
6/44 (13.6) |
| Histopathology, n = 44 | |
| Mixed cell, suppurative granuloma | 36/44 (81.8) |
| Nonspecific granulomatous inflammation | 3/44 (6.8) |
| Evidence of fungus observed |
0/44 (0.0) |
| Outcome | |
| Completely cured | 41 (83.7) |
| Lost to follow-up |
8 (16.3) |
| Treatment duration | |
| Median duration until improved, d (IQR) | 46 (30–90) |
| Mean duration until cured, d (IQR), n = 41 | 180 (141–240) |
*Values are no. patients/total no. patients (%) except as indicated. IQR, interquartile range. †Other occupations included teacher, monk, and boat driver.
Page created: September 24, 2024
Page updated: November 26, 2024
Page reviewed: November 26, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.